Prognostic values of combined ratios of white blood cells in glioma: a systematic review and meta-analysis

Gliomas, the most prevalent type of neurological tumor, pose a challenging prognosis for patients. Recent studies have underscored the importance of inflammatory markers such as the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR) in predicting...

Full description

Saved in:
Bibliographic Details
Published in:Neurosurgical review 2024-10, Vol.47 (1), p.831, Article 831
Main Authors: Zhou, JiaNuo, Tan, Botao, Gao, Feng
Format: Article
Language:English
Subjects:
Brain Neoplasms - blood
Brain Neoplasms - mortality
Brain Neoplasms - pathology
Glioma - blood
Glioma - mortality
Glioma - pathology
Humans
Leukocyte Count
Leukocytes
Lymphocytes
Medicine
Medicine & Public Health
Neurosurgery
Neutrophils
Prognosis
Review
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gliomas, the most prevalent type of neurological tumor, pose a challenging prognosis for patients. Recent studies have underscored the importance of inflammatory markers such as the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR) in predicting the prognosis of gliomas. We undertook a thorough meta-analysis to elucidate the role of these inflammatory markers in forecasting the prognosis of glioma patients. We extracted hazard ratios (HR) and their corresponding 95% confidence intervals (95% CI) from each study for analysis. To assess heterogeneity and identify influential studies, we conducted sensitivity analysis. Subgroup analysis was performed to investigate sources of heterogeneity, and we employed Egger’s test to evaluate publication bias in the meta-analysis. Higher NLR levels were associated with shorter overall survival (HR = 1.46, 95% CI: 1.33–1.60) and progression-free survival (HR = 1.24, 95% CI: 1.04–1.48). There was no significant correlation between PLR levels and overall survival (HR = 1.01, 95% CI: 1.00–1.01) or progression-free survival (HR = 1.00, 95% CI: 0.98–1.02) in glioma patients. Elevated MLR levels were associated with decreased overall survival in glioma patients (HR = 1.78, 95% CI: 1.36–2.34). SII levels did not show any significant association with overall or progression-free survival in glioma patients (HR = 1.00, 95% CI: 0.99–1.01).In the sensitivity analysis, two studies potentially contributed to the instability. Subgroup analyses showed patient population and area were identified as potential sources of heterogeneity. Egger's test showed that there was publication bias in the relationship between NLR and PLR and overall survival ( P  
ISSN:1437-2320
1437-2320
DOI:10.1007/s10143-024-03064-x